or Try an Advanced Search...

    Technical Analysis for CTXR - Citius Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    F 0.54 -6.92% -0.04
    CTXR closed down 6.92 percent on Monday, July 1, 2024, on 1.24 times normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical CTXR trend table...
    Date Alert Name Type % Chg
    MACD Bearish Signal Line Cross Bearish 0.00%
    New 52 Week Closing Low Bearish 0.00%
    New 52 Week Low Weakness 0.00%
    Gapped Up Strength 0.00%
    Below Lower BB Weakness 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Fell Below 20 DMA Bearish -6.92%
    New 52 Week Closing Low Bearish -6.92%
    Volume Surge Other -6.92%
    Older End-of-Day Signals for CTXR ...

       Recent Intraday Alerts

    Alert Time
    Down 1 ATR about 5 hours ago
    Down 5% about 8 hours ago
    Down 3% about 9 hours ago
    Fell Below Previous Day's Low about 9 hours ago
    Down 2 % about 9 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    CTXR Chart by TradingView
    Basic chart:

    Profile

    Citius Pharmaceuticals, Inc. Description

    Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care, and prescription products. Its product candidates include Mino-Lok and Hydrocortisone-Lidocaine Cream. The Company's Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. The Company's Hydrocortisone-Lidocaine topical formulation provides anti-inflammation and anesthetic relief to persons suffering from hemorrhoids. Its Mino-Lok product for the treatment of catheter related bloodstream infections has completed Phase IIb and is entering Phase III trials. It is reformulating Hydrocortisone-Lidocaine product and will be entering Phase IIb trials in 2017. As of September 30, 2016, the Company had not generate any revenues.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Pharmaceutical Drugs Inflammation Catheter Antibiotics Cancer Care Care Products Prescription Product Prescription Products Acetamides Bloodstream Infections Lidocaine

    Is CTXR a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 11 Sidoti Events, LLC's Virtual June Small-Cap Conference
    May 29 Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
    May 21 Citius gains as late-stage trial for Mino-Lok succeeds
    May 21 Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
    May 14 Citius Pharmaceuticals Non-GAAP EPS of -$0.05
    May 14 Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update
    May 10 Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences
    Apr 30 Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering
    Apr 26 Citius Pharmaceuticals to raise $15M through direct offering; shares fall
    Apr 26 Citius Pharmaceuticals Announces $15 Million Registered Direct Offering
    See more CTXR news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 1.28
    52 Week Low 0.5254
    Average Volume 1,995,281
    200-Day Moving Average 0.73
    50-Day Moving Average 0.67
    20-Day Moving Average 0.63
    10-Day Moving Average 0.62
    Average True Range 0.05
    RSI (14) 36.71
    ADX 16.75
    +DI 19.70
    -DI 21.26
    Chandelier Exit (Long, 3 ATRs) 0.56
    Chandelier Exit (Short, 3 ATRs) 0.69
    Upper Bollinger Bands 0.68
    Lower Bollinger Band 0.57
    Percent B (%b) -0.26
    BandWidth 17.29
    MACD Line -0.02
    MACD Signal Line -0.02
    MACD Histogram -0.0034
    Fundamentals Value
    Market Cap 86.37 Million
    Num Shares 159 Million
    EPS -0.22
    Price-to-Earnings (P/E) Ratio -2.47
    Price-to-Sales 0.00
    Price-to-Book 1.16
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.67
    Resistance 3 (R3) 0.68 0.65 0.65
    Resistance 2 (R2) 0.65 0.61 0.64 0.64
    Resistance 1 (R1) 0.59 0.59 0.58 0.59 0.64
    Pivot Point 0.56 0.56 0.55 0.56 0.56
    Support 1 (S1) 0.51 0.53 0.49 0.50 0.45
    Support 2 (S2) 0.47 0.51 0.47 0.44
    Support 3 (S3) 0.42 0.47 0.44
    Support 4 (S4) 0.42